Beacon Investment Advisory Services Inc. Makes New Investment in Incyte Corporation $INCY

Posted by Brenda Bartman on Sep 10th, 2026

Beacon Investment Advisory Services Inc. acquired a new stake in Incyte Corporation (NASDAQ:INCY – Free Report) during the second quarter, Holdings Channel.com reports. The fund acquired 5,608 shares of the biopharmaceutical company’s stock, valued at approximately $636,000.

A number of other hedge funds have also recently made changes to their positions in INCY. Greenleaf Trust increased its position in shares of Incyte by 2.8% during the second quarter. Greenleaf Trust now owns 3,358 shares of the biopharmaceutical company’s stock worth $381,000 after acquiring an additional 93 shares in the last quarter. Jacobi Capital Management LLC lifted its position in Incyte by 0.9% in the 4th quarter. Jacobi Capital Management LLC now owns 10,613 shares of the biopharmaceutical company’s stock valued at $1,048,000 after acquiring an additional 99 shares in the last quarter. Oregon Public Employees Retirement Fund lifted its position in Incyte by 0.5% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 18,870 shares of the biopharmaceutical company’s stock valued at $1,864,000 after acquiring an additional 100 shares in the last quarter. Smartleaf Asset Management LLC boosted its stake in Incyte by 7.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,628 shares of the biopharmaceutical company’s stock valued at $161,000 after purchasing an additional 113 shares during the last quarter. Finally, Bank of Nova Scotia boosted its stake in Incyte by 0.7% during the 2nd quarter. Bank of Nova Scotia now owns 17,041 shares of the biopharmaceutical company’s stock valued at $1,160,000 after purchasing an additional 124 shares during the last quarter. 96.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Incyte

In related news, EVP Patrick A. Mayes sold 41,899 shares of Incyte stock in a transaction on Friday, July 31st. The stock was sold at an average price of $119.46, for a total transaction of $5,005,254.54. Following the sale, the executive vice president directly owned 61,441 shares in the company, valued at approximately $7,339,741.86. This trade represents a 40.54% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Pablo J. Cagnoni sold 10,801 shares of the business’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $125.56, for a total value of $1,356,173.56. Following the completion of the transaction, the insider directly owned 183,200 shares in the company, valued at approximately $23,002,592. This represents a 5.57% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 16.20% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on INCY. Oppenheimer reissued a “market perform” rating and issued a $120.00 price objective on shares of Incyte in a research note on Tuesday, July 28th. Weiss Ratings raised Incyte from a “buy (b-)” rating to a “buy (b)” rating in a research report on Wednesday, July 29th. Stifel Nicolaus set a $145.00 price target on Incyte in a report on Tuesday, July 28th. Canaccord Genuity Group assumed coverage on Incyte in a report on Thursday, August 20th. They set a “buy” rating and a $152.00 price target for the company. Finally, BMO Capital Markets reissued a “market perform” rating on shares of Incyte in a research report on Tuesday, September 1st. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and twelve have issued a Hold rating to the company’s stock. According to MarketBeat.com, Incyte has a consensus rating of “Moderate Buy” and an average price target of $124.05.

View Our Latest Stock Report on Incyte

Incyte Stock Performance

Shares of INCY stock opened at $126.01 on Thursday. Incyte Corporation has a 52-week low of $81.09 and a 52-week high of $132.60. The company has a 50-day simple moving average of $121.58 and a two-hundred day simple moving average of $106.40. The company has a market capitalization of $25.54 billion, a price-to-earnings ratio of 16.05, a PEG ratio of 3.62 and a beta of 0.77.

Incyte (NASDAQ:INCY – Get Free Report) last posted its quarterly earnings data on Tuesday, July 28th. The biopharmaceutical company reported $3.09 EPS for the quarter, beating the consensus estimate of $2.15 by $0.94. Incyte had a net margin of 27.71% and a return on equity of 29.93%. The firm had revenue of $1.67 billion during the quarter, compared to analyst estimates of $1.50 billion. During the same quarter last year, the business posted $1.57 EPS. The company’s revenue for the quarter was up 37.7% on a year-over-year basis. On average, sell-side analysts forecast that Incyte Corporation will post 2.64 EPS for the current fiscal year.

Incyte Company Profile

(Free Report)

Incyte Corporation is a biopharmaceutical company focused on discovering, developing and commercializing medicines for oncology and inflammatory diseases. Founded in 1991 and headquartered in Wilmington, Delaware, the company conducts research in areas including oncology, hematology, immunology and dermatology.

Incyte’s commercial portfolio includes Jakafi (ruxolitinib), a treatment for certain myelofibrosis, polycythemia vera and graft-versus-host disease; Opzelura (ruxolitinib) cream for atopic dermatitis and nonsegmental vitiligo; and Pemazyre (pemigatinib) for selected cancers involving abnormal FGFR signaling.